Phase 2 Trial Utilizing Zanubrutinib in Patients With Diffuse Large B-cell Lymphoma and MYD88 L265P Mutations, CD79B Mutations, NOTCH1 Truncation or Who Are CD5+ by IHC.
This study is testing a medication called zanubrutinib to see if it effectively treats a specific type of fast-growing blood cancer called DLBCL. By focusing on patients with certain genetic markers, researchers hope to find a more personalized and effective way to fight these cancer cells.
You may be eligible if you are at least 18 years old and have a confirmed diagnosis of DLBCL with specific genetic changes or protein markers. You must also be early in your treatment journey, specifically having received no more than one cycle of standard chemotherapy.
Participants will take zanubrutinib, a pill designed to block signals that help cancer cells grow. Throughout the study, your medical team will closely monitor your health and how your cancer responds to the treatment.
This study is currently recruiting new participants at a medical facility in Richmond, Virginia. If you are interested, please speak with your doctor to see if this location and study are right for you.
- 1The study investigates a targeted pill that blocks cancer growth signals.
- 2Participation is limited to patients with specific genetic mutations or protein markers in their cancer cells.
- 3The trial is for patients who are just beginning their treatment plan.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.